Tiny virus may hold key to kidney cancer treatment success
NCT ID NCT07018037
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This pilot study is looking at whether levels of a common virus called TTV can help predict how well immunotherapy works in people with advanced kidney cancer. Researchers will measure TTV levels in 20 patients before and during their first immunotherapy treatment. The goal is to see if the virus could serve as a simple biomarker to guide treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could lead to a simple blood test to predict which kidney cancer patients will benefit from immunotherapy.
What could go wrong
This is a very small pilot study (20 people) that only observes virus levels, not treatment outcomes. It may not find a clear link or be too early to guide treatment decisions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
"Regina Elena" National Cancer Institute
RECRUITINGRome, Rome, 00144, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••